There is much interest in inhaled antibiotics these days. Prima facie, the logic for this approach is compelling: Getting the antibiotic (and a lot of it) directly to the site of infection, while avoiding systemic toxicity, sounds like optimized efficacy
Continue reading Antibiotic Inhalers Galore (Part 1): More Combinations and Permutations than a Rubik’s Cube → Like this: Like Loading...
Posted in QIDP Antibiotics, Recent Literature, The News, The Viewpoint |
Tagged Aeroquin, aerosolized antibiotics, AeroVanc, amikacin, amphotericin, antibiotic blog, Aradigm, Arikayce, aspergillus, azithromycin, aztreonam, Bayer, Bayhaler, bronchiectasis, Cardeas, Cayston, ceftazidime, CF, ciprofloxacin, colistin, Colobreathe, CURx, cystic fibrosis, Dalvance, daptomycin, doxycycline, fosfomycin, gentamicin, Gilead, Harald Reinhart, Horizon, IASIS, imipenem, inhaled antibiotics, inhaler business, Insmed, levofloxacin, Meiji, meropenem, Merrem, MRSA, NCFB, NCFBE, nebulized antibiotics, Nebupent, Novartis, NTM, PCP prophylaxis, pentamidine, pseudomonas, Pulmaquin, QIDP, Quinsair, Savara, surfactant, tetracycline, Teva, TOBI, tobi Podhaler, tobramycin, VABP, vancomycin, VAP |
Fosfomycin Who would have thought that a drug that has been around since 1969  could become eligible for QIDP status in 2015? Well, Zavante Therapeutics recently garnered the coveted QIDP designation for fosfomycin IV. This formulation has been available
Continue reading A Renaissance for Old Drugs: Fosfomycin and Colistin → Like this: Like Loading...
Posted in QIDP Antibiotics, The Viewpoint |
Tagged acinetobacter, antibiotic blog, Avycaz, carbapenem-resistant enterobacteriaceae, carbenicillin, Ceftazidime/avibactam, CEPA, colistimethate, colistin, colistin dosing, CRE, E. faecalis, E. faecium, enterococci, ESBL, fosfomycin, inhalational antibiotics, KPC, Mandell, MDR pathogens, Merck, MRSA, P. aeruginosa, pseudomonas, synergy, thiamphenicol, ticarcillin, tigecycline, Tygacil, Zavante Therapeutics |
In this day and age, few truly broad spectrum antibiotics are in development, although this does not hold true for narrow-spectrums. Just think of all the MRSA drugs (quinolones, FabI inhibitors), the pseudomonas drugs (NCEs and monoclonals) or some narrow
Continue reading Artie’s Law: Avoid Bad Advice and Don’t Follow ‘Mission Impossible’ Advice → Like this: Like Loading...
Posted in The Viewpoint |
Tagged Achaogen, Advanced Life Sciences, ALS, antibiotic blog, Artie’s law, carbapenem-resistance, Cethromycin, colistin, CRE, development of MDR-pathogen antibiotics, development of narrow spectrum antibiotics, erythromycin, FabI inhibitor, FDA Guidance, J&J, ketolide, Lasagna’s law, LpxC inhibitors, MDR pathogens, MDR S. pneumonia, monoclonal antibodies, MRSA, Muench’s Third law, ofloxacin, Ortho, plazomicin, POL7080, pseudomonas, quinolones, Restanza |
There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature,
Continue reading What is the “Niche” for Ceftolozane / Tazobactam? → Like this: Like Loading...
Posted in QIDP Antibiotics, The News, The Viewpoint |
Tagged adverse events, aminoglycoside, AmpC, antibiotic blog, avibactam, beta-lactamase, carbapenem, ceftazidime, ceftolozane, ceftolozane/tazobactam, cephalosporin, cIAI, ciprofloxacin, colistin, CRE, cUTI, CXA-101, ESBL, Fast Track, FDA approval, KPC, meropenem, P. aeruginosa, piperacillin/tazobactam, plazomicin, Priority Review, pseudomonas, safety, tazobactam, VABP, Zerbaxa |
A recent publication  from the team which brought us the Meningococcal B vaccine is of interest from the perspective of vaccine development strategy and feasibility. Link to this post!
Like this: Like Loading...
Posted in Recent Literature |
Tagged antibiotic blog, bacterial vaccine targets, BCG vaccine, C. difficile, Cholera vaccine, EF-Tu, elongation factor, ETEC, GAS, GBS, Group A streptococcus, Group B streptococcus, Klebsiella, LFF-571, Novartis, opsonizing antibodies, pseudomonas, S. aureus vaccine, shigella, T-cell immunity, TB, tuberculosis, V710 vaccine |